BioMarin's Acquisition of Amicus Therapeutics Enhances Rare Disease Portfolio

BioMarin Completes Acquisition of Amicus Therapeutics

On April 27, 2026, BioMarin Pharmaceutical Inc. announced the successful completion of its acquisition of Amicus Therapeutics. This strategic move, valued at approximately $4.8 billion, allows BioMarin to broaden its commercial portfolio significantly.

Details of the Acquisition

BioMarin acquired Amicus for $14.50 per share in an all-cash transaction. This acquisition adds two innovative treatments for lysosomal storage diseases to BioMarin’s already impressive lineup: Galafold (migalastat) and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat). These therapies represent vital advancements in the treatment of rare diseases such as Fabry disease and Pompe disease.

Galafold, a pioneering oral medication, is specifically designed for individuals with Fabry disease who possess amenable GLA variants. It works by stabilizing the body's natural enzyme, consequently helping to clear harmful substance accumulation. BioMarin’s acquisition enables it to expand the availability of Galafold, which is already approved in over 40 countries, including the United States, Europe, and Japan.

Pombiliti and Opfolda, used together, form a two-component therapy targeting patients with late-onset Pompe disease who are not responding to existing enzyme replacement therapies. This combination is pivotal as it enhances the delivery and retention of enzyme functionality in the body, offering hope to patients grappling with this debilitating condition.

CEO Statement

Alexander Hardy, BioMarin’s President and CEO, emphasized the acquisition's significance, stating that it not only reinforces their growth strategy but also aligns with the company's mission to deliver essential medicines to those affected by rare diseases. Hardy articulated the synergy created by combining BioMarin’s global presence and robust commercial infrastructure with the strong legacy of Amicus Therapeutics, affirming their commitment to enhance patient access to these critical therapies worldwide.

Future Directions

In addition to gaining these valuable treatments, BioMarin also acquired the U.S. rights to DMX-200, an investigational drug that could potentially treat focal segmental glomerulosclerosis (FSGS), a rare kidney disease currently in Phase 3 trials. This addition emphasizes BioMarin's dedication to pursuing innovative solutions in the treatment landscape of rare diseases.

Conclusion

The completion of this acquisition marks a significant milestone for BioMarin and its ongoing efforts in the biotech domain. With a robust pipeline and a historical commitment to innovation, BioMarin is more equipped than ever to address the complexities associated with rare diseases, ultimately reaching out to more patients who depend on these pioneering treatments. As BioMarin moves forward, it promises to provide updated financial guidance and further insights during its upcoming First Quarter Earnings Call on May 4, 2026.

BioMarin's strategic endeavors exemplify the vital role of mergers and acquisitions in the biotechnology sector, particularly in enhancing treatment options for patients battling rare diseases. With this latest acquisition, BioMarin is set to not only strengthen its market position but also to continue making a lasting impact on patients' lives around the globe.